Literature DB >> 24214030

Monoclonal antibody preparation and expression profile analysis of a novel hepatoma associated gene.

Yanhong Liu1, Jie Song, Yuehui Li, Yanjie Zhao, Qiang Ju, Guohua Zhou, Guancheng Li.   

Abstract

Hepatoma associated gene (HTA), a gene screened and cloned by our previous research, was specifically expressed in certain kinds of tumors and had a cancer-promoting role in hepatocellular carcinoma (HCC). To further elucidate the mechanism of HTA in hepatoma carcinogenesis and its potential role as a cancer biomarker, refolded HTA protein (HTA) was obtained by prokaryotic recombinant expression system and immobilized metal affinity chromatography. Then anti-HTA monoclonal antibody (mAb) was produced by hybridoma technique. Using the high titer anti-HTA mAb with high specificity obtained, the expression profile of HTA was analysed by immunohistochemistry staining. It showed that HTA expressed specifically in some kinds of tumors, and didn't express in almost any of the normal tissues. The positive expression rate and expression quantity of HTA was significantly higher in HCC tissues than in hepatic cirrhosis tissues, hepatic fibrosis tissues and normal hepatic tissues. The expression of HTA was positively correlated with hepatoma carcinogenic process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24214030     DOI: 10.1007/s12253-013-9703-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  23 in total

Review 1.  Technical refolding of proteins: Do we have freedom to operate?

Authors:  Maria K Eiberle; Alois Jungbauer
Journal:  Biotechnol J       Date:  2010-06       Impact factor: 4.677

Review 2.  Methods and protocols for prediction of immunogenic epitopes.

Authors:  Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  Brief Bioinform       Date:  2006-10-31       Impact factor: 11.622

Review 3.  Refolding solubilized inclusion body proteins.

Authors:  Richard R Burgess
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

4.  Expression and biological activity of genetic fusions between MalE, the maltose binding protein from Escherichia coli and portions of CD4, the T-cell receptor of the AIDS virus.

Authors:  J M Clément; M Jehanno; O Popescu; W Saurin; M Hofnung
Journal:  Protein Expr Purif       Date:  1996-11       Impact factor: 1.650

Review 5.  Newer markers for hepatocellular carcinoma.

Authors:  Jorge A Marrero; Anna S F Lok
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Hu-Liang Jia; Qing-Hai Ye; Lun-Xiu Qin; Anuradha Budhu; Marshonna Forgues; Yidong Chen; Yin-Kun Liu; Hui-Chuan Sun; Lu Wang; Hong-Zhou Lu; Fang Shen; Zhao-You Tang; Xin Wei Wang
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

7.  Identification of HTA as a novel-specific marker for human hepatocellular carcinoma.

Authors:  Yan Liu; Yuehui Li; Fengjie Guo; Miao Dai; Jiajia Wang; Jinyue Hu; Guancheng Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-04       Impact factor: 4.553

Review 8.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

9.  A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma.

Authors:  Laura F Steel; Donna Shumpert; Michael Trotter; Steven H Seeholzer; Alison A Evans; W Thomas London; Raymond Dwek; Timothy M Block
Journal:  Proteomics       Date:  2003-05       Impact factor: 3.984

Review 10.  Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Authors:  Mark A Feitelson; Helena M G P V Reis; N Lale Tufan; Bill Sun; Jingbo Pan; Zhaorui Lian
Journal:  Cancer Lett       Date:  2009-02-06       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.